Challenger becomes substantial holder in Integral Diagnostics and Telix Pharmaceuticals

Challenger Limited announced that it has become a substantial holder in Integral Diagnostics Limited (ASX:IDX) and Telix Pharmaceuticals Ltd (ASX:TLX), effective September 3, 2025. For Integral Diagnostics, Challenger and its associated entities acquired a 5.28% voting power, holding 19,657,417 ordinary fully paid securities. This interest was established through a series of on-market purchases, sales, and off-market transfers over the preceding four months.

Similarly, Challenger Limited and its entities gained a 5.00% voting power in Telix Pharmaceuticals Ltd, holding 16,927,111 ordinary fully paid securities. This position was also built through a combination of on-market transactions and off-market transfers. The transactions highlight a period of active portfolio adjustments by Challenger.

Separately, Challenger also reported the conversion of 397,787 performance rights into ordinary fully paid shares, effective September 1, 2025. These conversions were part of an employee incentive scheme, with key management personnel including Nicolas Hamilton, Anton Kapel, Alexandra Bell, and Victor Rodriguez participating. Following these conversions, the total number of ordinary fully paid securities on issue for Challenger Limited stands at 691,395,691.